Congressional Letter to Administration on Importance of Animal Biotechnology
October 8, 2021
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our food supply and sustainably meet demand. Ongoing research and existing innovations in animal genetics show great promise in addressing these challenges. However, an efficient, risk and science-based regulatory system that can create a safe, predictable path to market is imperative to capitalizing on these solutions. We believe the existing U.S. regulatory process for the review of animals developed or improved through biotechnology requires significant improvement to meet that standard, and we encourage the U.S. Department of Agriculture (USDA) and Food & Drug Administration (FDA) to continue working with each other and with other relevant federal partners to appropriately modernize this important process.
Download Full Comments Below
Congressional Letter to Administration on Importance of Animal Biotech
Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our food supply and sustainably meet demand. Ongoing research and existing innovations in animal genetics show great promise in addressing these challenges. However, an efficient, risk and science-based regulatory system that can create a safe, predictable path to market is imperative to capitalizing on these solutions. We believe the existing U.S. regulatory process for the review of animals developed or improved through biotechnology requires significant improvement to meet that standard, and we encourage the U.S. Department of Agriculture (USDA) and Food & Drug Administration (FDA) to continue working with each other and with other relevant federal partners to appropriately modernize this important process.